Side-by-side guide
Sermorelin vs CJC-1295 + Ipamorelin: the full guide
An honest, clinically-framed comparison of Sermorelin and CJC-1295 + Ipamorelin — what they do, how they differ, what the evidence shows, and who each tends to suit.
Quick comparison at a glance
The short version — here is how Sermorelin and CJC-1295 + Ipamorelin stack up on the questions most patients ask before picking one.
Sermorelin
- Drug class: GHRH analog (growth hormone releasing hormone fragment)
- Brand names: (compounded GHRH analog)
- Mechanism: 29-amino-acid fragment of GHRH that binds pituitary GHRH receptors and stimulates pituitary GH release in a natural pulsatile pattern. Preserves the feedback loop — if somatostatin is suppressing the pituitary, sermorelin won't override it.
- Dosing: Typically subcutaneous injection, nightly before bed (to match natural GH pulsatility). Dose ranges vary by protocol.
- Half-life: Short — about 10-20 minutes. Effect is brief and pulse-like.
- FDA indication: Not currently available as an FDA-approved finished drug product in the US for any indication. Historically was used as a diagnostic and therapeutic agent for growth hormone deficiency in children.
- FDA status: Not currently FDA-approved. Available only through compounding pharmacies under valid prescriptions.
- Manufacturer: Licensed compounding pharmacies.
- Common side effects: Injection site reactions, flushing, headache, dizziness. GH-related side effects like fluid retention and joint aches are less common with pulsatile secretagogue therapy than with exogenous HGH.
- Typical price range: Compounded sermorelin programs typically run $200-$400/month depending on pharmacy, dose, and duration.
CJC-1295 + Ipamorelin
- Drug class: GHRH analog (CJC-1295) + ghrelin receptor agonist (Ipamorelin)
- Brand names: (compounded stack)
- Mechanism: CJC-1295 is a modified GHRH analog with a longer half-life than native GHRH or sermorelin. Ipamorelin is a selective GH secretagogue receptor (GHSR / ghrelin receptor) agonist. Combined, the two stimulate GH release through two different pathways for a stronger and more sustained pulse.
- Dosing: Typically combined subcutaneous injection. Dosing protocols vary; common regimens involve daily or 5-days-per-week injection.
- Half-life: CJC-1295 without DAC: several hours. CJC-1295 with DAC (drug affinity complex): 6-8 days. Ipamorelin: approximately 2 hours. The combination produces a more sustained GH pulse than sermorelin.
- FDA indication: Neither is FDA-approved for any indication.
- FDA status: NOT FDA-approved. Available through compounding pharmacies under valid prescriptions.
- Manufacturer: Licensed compounding pharmacies.
- Common side effects: Similar profile to sermorelin — injection site reactions, flushing, headache. Because the combination produces stronger and more sustained GH pulses than sermorelin alone, fluid retention and joint aches may be somewhat more common.
- Typical price range: Compounded CJC-1295 + Ipamorelin stacks typically run $250-$450/month depending on pharmacy, dose, and whether DAC-modified CJC-1295 is used.
Why secretagogues are fundamentally different from HGH
Before comparing sermorelin and CJC-1295/Ipamorelin, it's worth understanding what GH secretagogues are and what they are not. This distinction matters because it is commonly blurred by marketing and because it has legal implications.
Growth hormone secretagogues work upstream. They stimulate your pituitary to release more of its own growth hormone in natural pulsatile patterns. The body's feedback loops remain intact — somatostatin can still suppress the pituitary when appropriate, and GH levels rise and fall naturally.
Exogenous HGH bypasses the pituitary entirely by injecting growth hormone directly into the bloodstream. This overrides the feedback loops, produces continuous rather than pulsatile GH levels, and has a different risk profile. Non-medical HGH use is also illegal in the US under 21 U.S.C. § 333(e) — it may only be dispensed for specific FDA-approved indications.
Sermorelin, CJC-1295, and Ipamorelin are not HGH. They are peptides that signal the pituitary. This is important both clinically (different risk profile) and legally (different regulatory category). Anyone who conflates the two is either uninformed or intentionally misleading you.
Two pathways, one result
Growth hormone release from the pituitary is controlled by two main signals:
- GHRH pathway. Growth hormone releasing hormone, produced in the hypothalamus, acts on pituitary GHRH receptors to stimulate GH release. Sermorelin and CJC-1295 are synthetic analogs that work on this pathway.
- Ghrelin/GHSR pathway. Ghrelin (the "hunger hormone") also stimulates GH release by binding the growth hormone secretagogue receptor (GHSR). Ipamorelin is a selective GHSR agonist that stimulates this pathway without the appetite and cortisol side effects of earlier ghrelin mimetics.
Sermorelin alone activates only the GHRH pathway. The CJC-1295 + Ipamorelin stack activates both the GHRH pathway (via CJC-1295) AND the ghrelin pathway (via Ipamorelin). Stimulating both pathways produces a stronger and more sustained GH pulse than stimulating either alone — this is why the stack is considered more "aggressive" than sermorelin monotherapy.
What to realistically expect
GH secretagogue peptides are not magic. Realistic expectations matter.
- Sleep quality improvements are among the most consistent reported benefits, typically noticed within the first few weeks. This is plausible given natural GH pulsatility is closely tied to deep sleep architecture.
- Body composition changes tend to be gradual and subtle, appearing over months rather than weeks, and depend heavily on pairing peptide therapy with resistance training, adequate protein intake, and sleep.
- Recovery from exercise may improve for some patients but this is not consistently reported and is hard to separate from placebo and confounding variables.
- Energy, mood, libido reports are mixed. Some patients report improvements; others don't. Individual response varies substantially.
Any provider promising dramatic transformations from GH peptides alone is not being honest with you. These are incremental tools that work best alongside the fundamentals of sleep, nutrition, and training.
Who tends to do better on each
There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.
Sermorelin
Sermorelin tends to fit adults who want a gentler, more physiological approach to growth hormone optimization — preserving the natural pulsatility and feedback loop. It is often a reasonable first step for patients considering GH peptide therapy, and may be prescribed off-label by physicians focused on age-related GH decline in appropriate candidates.
CJC-1295 + Ipamorelin
The CJC-1295/Ipamorelin stack tends to fit patients who want a more robust effect than sermorelin alone, or who haven't seen adequate response to sermorelin monotherapy. The stack is also commonly chosen by physicians focused on body composition changes where a stronger GH signal is clinically desired.
A prescription is not guaranteed. Your Puri-affiliated provider may decline to prescribe either medication if the clinical picture does not support it, if you have a contraindication, or if a different treatment is more appropriate for your situation. You will not be charged for medication you do not receive.
